| scholarly article | Q13442814 |
| P2093 | author name string | Anthony Trela | |
| Robert G Hamilton | |||
| Kari C Nadeau | |||
| Philippe Bégin | |||
| Tina Dominguez | |||
| Gerri O'Riordan | |||
| Scott Seki | |||
| Alanna Blakemore | |||
| Anjuli Mehrotra | |||
| Bethany Kausch | |||
| Elisabeth Hoyte | |||
| Liane Bacal | |||
| Shruti P Wilson | |||
| Morvarid Tavassoli | |||
| P2860 | cites work | Allergen-specific oral immunotherapy for peanut allergy | Q24200573 |
| Oral rush desensitization to egg: efficacy and safety | Q39205396 | ||
| Double-blind, placebo-controlled food challenge (DBPCFC) as an office procedure: a manual | Q39549466 | ||
| Food allergen sensitization in inner-city children with asthma | Q39715384 | ||
| Immunologic effects of omalizumab in children with severe refractory atopic dermatitis: a randomized, placebo-controlled clinical trial | Q42139482 | ||
| Specific oral tolerance induction with raw hen's egg in children with very severe egg allergy: a randomized controlled trial | Q45847519 | ||
| Food allergies in children affect nutrient intake and growth. | Q50710913 | ||
| Oral peanut immunotherapy in children with peanut anaphylaxis. | Q52903267 | ||
| The prevalence, severity, and distribution of childhood food allergy in the United States. | Q53085704 | ||
| Specific oral tolerance induction in children with very severe cow's milk–induced reactions | Q57243160 | ||
| Specific oral tolerance induction in food allergy in children: efficacy and clinical patterns of reaction | Q66829364 | ||
| The impact of childhood food allergy on quality of life | Q77431896 | ||
| Sublingual immunotherapy for cow's milk protein allergy: a preliminary report | Q80190729 | ||
| A protocol for oral desensitization in children with IgE-mediated cow's milk allergy | Q80413023 | ||
| Combination treatment with omalizumab and rush immunotherapy for ragweed-induced allergic rhinitis: Inhibition of IgE-facilitated allergen binding | Q80614064 | ||
| Sublingual immunotherapy for hazelnut food allergy: a randomized, double-blind, placebo-controlled study with a standardized hazelnut extract | Q81454014 | ||
| Oral immunotherapy for cow's milk allergy with a weekly up-dosing regimen: a randomized single-blind controlled study | Q82340072 | ||
| Cow's milk epicutaneous immunotherapy in children: a pilot trial of safety, acceptability, and impact on allergic reactivity | Q84183803 | ||
| Overall prevalence of self-reported food allergy in Canada | Q84739401 | ||
| The economic impact of childhood food allergy in the United States | Q85862163 | ||
| ??? | Q28257778 | ||
| Future therapies for food allergies | Q24630319 | ||
| Effect of anti-IgE therapy in patients with peanut allergy | Q28183354 | ||
| A phase II, randomized, double‑blind, parallel‑group, placebo‑controlled oral food challenge trial of Xolair (omalizumab) in peanut allergy | Q28307175 | ||
| Safety and feasibility of oral immunotherapy to multiple allergens for food allergy | Q34398080 | ||
| Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis. | Q34480913 | ||
| Successful oral tolerance induction in severe peanut allergy | Q34604676 | ||
| A randomized controlled study of peanut oral immunotherapy: clinical desensitization and modulation of the allergic response | Q34698506 | ||
| The natural history of egg allergy | Q34724072 | ||
| Management of the patient with multiple food allergies | Q34766800 | ||
| A pilot study of omalizumab to facilitate rapid oral desensitization in high-risk peanut-allergic patients | Q35510416 | ||
| Basophil CD203c levels are increased at baseline and can be used to monitor omalizumab treatment in subjects with nut allergy | Q35546493 | ||
| Clinical safety of Food Allergy Herbal Formula-2 (FAHF-2) and inhibitory effect on basophils from patients with food allergy: Extended phase I study | Q35589689 | ||
| Changes in antigen-specific T-cell number and function during oral desensitization in cow's milk allergy enabled with omalizumab | Q35894673 | ||
| Rapid oral desensitization in combination with omalizumab therapy in patients with cow's milk allergy | Q36093954 | ||
| Oral immunotherapy for treatment of egg allergy in children | Q36180099 | ||
| The safety and efficacy of sublingual and oral immunotherapy for milk allergy. | Q36220764 | ||
| Suppression of the basophil response to allergen during treatment with omalizumab is dependent on 2 competing factors | Q36368450 | ||
| The safety of peanut oral immunotherapy in peanut-allergic subjects in a single-center trial | Q36421592 | ||
| Anti-immunoglobulin E monoclonal antibody administered with immunotherapy | Q36488081 | ||
| Sublingual immunotherapy for peanut allergy: a randomized, double-blind, placebo-controlled multicenter trial | Q36548283 | ||
| A randomized, double-blind, placebo-controlled study of milk oral immunotherapy for cow's milk allergy | Q37150568 | ||
| Prevalence of self-reported food allergy in the National Health and Nutrition Examination Survey (NHANES) 2007-2010. | Q37293660 | ||
| Clinical efficacy and immune regulation with peanut oral immunotherapy | Q37301616 | ||
| Safety of a peanut oral immunotherapy protocol in children with peanut allergy | Q37316978 | ||
| Advances in immunotherapy for food allergy | Q37319886 | ||
| Kinetics of mast cell, basophil, and oral food challenge responses in omalizumab-treated adults with peanut allergy | Q37604549 | ||
| Specific oral tolerance induction in food allergic children: is oral desensitisation more effective than allergen avoidance?: a meta-analysis of published RCTs. | Q37762634 | ||
| Oral immunotherapy and anti-IgE antibody-adjunctive treatment for food allergy | Q37975653 | ||
| Managing food allergy in childhood | Q38039309 | ||
| Use of omalizumab in the treatment of food allergy and anaphylaxis | Q38052066 | ||
| Oral immunotherapy for food allergy: towards a new horizon | Q38070681 | ||
| Novel approaches to food allergy | Q38074866 | ||
| Anti-IgE--emerging opportunities for Omalizumab | Q38091754 | ||
| Food allergy: management, diagnosis and treatment strategies. | Q38119552 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | immunotherapy | Q1427096 |
| P304 | page(s) | 7 | |
| P577 | publication date | 2014-02-20 | |
| P1433 | published in | Allergy, Asthma & Clinical Immunology | Q15727057 |
| P1476 | title | Phase 1 results of safety and tolerability in a rush oral immunotherapy protocol to multiple foods using Omalizumab | |
| P478 | volume | 10 |
| Q64288585 | A Phase 2 Randomized Controlled Multisite Study Using Omalizumab-facilitated Rapid Desensitization to Test Continued vs Discontinued Dosing in Multifood Allergic Individuals |
| Q38981931 | Advances in food allergy oral immunotherapy: toward tolerance. |
| Q55004495 | Allergen-Specific Immunotherapies for Food Allergy. |
| Q51016355 | Allergen-specific IgG antibody signaling through FcγRIIb promotes food tolerance. |
| Q42091038 | Anti-IgE Treatment for Disorders Other Than Asthma |
| Q47192743 | Anti-IgE treatment with oral immunotherapy in multifood allergic participants: a double-blind, randomised, controlled trial. |
| Q48292169 | B-FAHF-2 plus oral immunotherapy (OIT) is safer and more effective than OIT alone in a murine model of concurrent peanut/tree nut allergy. |
| Q57035725 | Biomarkers in Food Allergy |
| Q90608343 | CSACI guidelines for the ethical, evidence-based and patient-oriented clinical practice of oral immunotherapy in IgE-mediated food allergy |
| Q38944010 | Cashew Nut Allergy: Clinical Relevance and Allergen Characterisation. |
| Q48282763 | Combining anti-IgE with oral immunotherapy. |
| Q26784498 | Current Options for the Treatment of Food Allergy |
| Q87850112 | Current Status of Potential Therapies for IgE-Mediated Food Allergy |
| Q64241041 | Current Strategies to Inhibit High Affinity FcεRI-Mediated Signaling for the Treatment of Allergic Disease |
| Q39050465 | Deciphering the black box of food allergy mechanisms. |
| Q55710000 | Deep TCR repertoire sequencing reveals relative change in peanut specific clonotype in subjects undergoing rush oral immunotherapy. |
| Q98464728 | Efficacy of long-term treatment with omalizumab in a food and inhalant allergy patient |
| Q46095219 | Elimination diet and the development of multiple tree-nut allergies |
| Q38692435 | Emerging Approaches to Food Desensitization in Children |
| Q89397460 | Enhancing the Safety and Efficacy of Food Allergy Immunotherapy: a Review of Adjunctive Therapies |
| Q47171873 | Feasibility of sustained response through long-term dosing in food allergy immunotherapy |
| Q64963813 | Food Allergies: Current and Future Treatments. |
| Q36229922 | Food allergy and the gut. |
| Q37442005 | Food allergy: immune mechanisms, diagnosis and immunotherapy |
| Q38543015 | Food specific oral immunotherapy: a potential treatment for food allergy |
| Q37554168 | IgE-Related Chronic Diseases and Anti-IgE-Based Treatments |
| Q90113914 | Immunoglobulin E (IgE)-Mediated Food Allergy in Children: Epidemiology, Pathogenesis, Diagnosis, Prevention, and Management |
| Q26795564 | Immunoglobulin E in irritable bowel syndrome: another target for treatment? A case report and literature review |
| Q48256010 | Immunoglobulin G; structure and functional implications of different subclass modifications in initiation and resolution of allergy. |
| Q50140616 | Immunotherapy for IgE-mediated wheat allergy |
| Q37106401 | Improving the safety of oral immunotherapy for food allergy |
| Q51305831 | Individually dosed omalizumab: an effective treatment for severe peanut allergy. |
| Q49025332 | International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis |
| Q35939076 | Long-term treatment with egg oral immunotherapy enhances sustained unresponsiveness that persists after cessation of therapy |
| Q49949791 | Modified Allergens for Immunotherapy |
| Q90227144 | Modulating Shrimp Tropomyosin-Mediated Allergy: Hypoallergen DNA Vaccines Induce Regulatory T Cells to Reduce Hypersensitivity in Mouse Model |
| Q35984123 | Molecular and cellular mechanisms of food allergy and food tolerance. |
| Q39912754 | Multiple-allergen oral immunotherapy improves quality of life in caregivers of food-allergic pediatric subjects |
| Q38565704 | New developments in immunotherapies for food allergy |
| Q55380934 | Novel strategies in immunotherapy for allergic diseases. |
| Q47139143 | Observational long-term follow-up study of rapid food oral immunotherapy with omalizumab |
| Q38517653 | Off-Label Uses of Omalizumab. |
| Q52321196 | Oral and Sublingual Immunotherapy for Treatment of IgE-Mediated Food Allergy. |
| Q41399825 | Oral immunotherapy and anti-IgE antibody treatment for food allergy |
| Q52757118 | Oral immunotherapy for food allergy. |
| Q38235447 | Oral immunotherapy for food allergy: mechanisms and role in management |
| Q38271442 | Oral immunotherapy for the treatment of food allergy |
| Q46615110 | Oral immunotherapy in clinical practice |
| Q28073074 | Personalized Medicine in Allergy |
| Q38569684 | Pharmacologic options for the treatment and management of food allergy |
| Q43117198 | Powder milk: a user-friendly and safe product for heated-milk food challenge? |
| Q93198143 | Protocol for a double-blind, randomized controlled trial on the dose-related efficacy of omalizumab in multi-food oral immunotherapy |
| Q26796442 | Recent advances in immunotherapy and vaccine development for peanut allergy |
| Q96136750 | Sialylation of immunoglobulin E is a determinant of allergic pathogenicity |
| Q41952022 | Successful desensitization in a boy with severe cow's milk allergy by a combination therapy using omalizumab and rush oral immunotherapy |
| Q38753106 | The Heterogeneity of Oral Immunotherapy Clinical Trials: Implications and Future Directions |
| Q55047196 | The Nuts and Bolts of Food Immunotherapy: The Future of Food Allergy. |
| Q34532292 | The Potential of Anti-IgE in Food Allergy Therapy |
| Q38954322 | The Use of Omalizumab in Food Oral Immunotherapy. |
| Q47897158 | The current state of food allergy therapeutics |
| Q38278145 | The evolution of allergen and non-specific immunotherapy: past achievements, current applications and future outlook |
| Q34437865 | The role of commensal bacteria in the regulation of sensitization to food allergens |
| Q38809512 | Treatment of allergic children - Where is the progress (for the practicing allergist)? |
| Q35186257 | Two year effects of food allergen immunotherapy on quality of life in caregivers of children with food allergies |
| Q39428534 | Update on oral immunotherapy for egg allergy |
| Q52850847 | [Allergen-specific immunotherapy for food allergies in childhood. Current options and future perspectives]. |
Search more.